The Cost-effectiveness Analysis of Three Therapeutic Schemes for Lower Respiratory Tract Infections / 中国药房
China Pharmacy
; (12): 92-94, 2001.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-411528
Responsible library:
WPRO
ABSTRACT
OBJECTIVE:
To evaluate the pharmacoeconomic effectiveness of three therapeutic schemes for lower respiratory tract infections.METHODS:
The cost-effectiveness analysis of three therapeutic schemes for lower respiratory tract infections was carried out.RESULTS:
The cost-effectiveness ratio of penicillin-piperacillin schemes(L1)was minimum in respect to the effective rate.However,the cost-effectiveness ratios had no significant difference between cefotaxime scheme(L3)and L1 scheme in regard to cure rate(P>0.05),the cost-effectiveness ratio of ciprofloxacin-clinadmacin scheme(L2) was higher significantly than those of L1 and L3 schemes(P<0.05,both schemes).CONCLUSION: L1 is the best therapeutic scheme.Although L3 scheme had higher cost,it had higher cure rate and lower ADRs occurrence.L3 scheme is benefitial to improvement of patient's life quality.
Full text:
Available
Health context:
Sustainable Health Agenda for the Americas
Health problem:
Goal 4: Health financing
Database:
WPRIM (Western Pacific)
Type of study:
Health economic evaluation
Language:
Chinese
Journal:
China Pharmacy
Year:
2001
Document type:
Article